Yahoo Finance1mon
Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers
which will be translated to the clinic to monitor target engagement and modulation. DPTX3496 shows down-regulation of beta catenin-driven gene transcription and Wnt pathway activity in vivo ...
Mena FN1mon
Ridymo® Designs Cyclic Peptide For Undruggable Β-Catenin Target Within Two Months
(MENAFN- PR Newswire) The Wnt/β-catenin pathway plays a crucial role in various biological functions and is implicated in multiple cancers[1-3]. Despite its importance as a therapeutic target[4-7 ...
Longview News-Journal1mon
RiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin Target Within Two Months
BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically ...